MedTrace Logo

Cardiac Resynchronisation Therapy and AV Nodal Ablation Trial in Atrial Fibrillation Patients (CAAN-AF)

NCT01522898 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 145

Last updated 2020-11-13

No results posted yet for this study

Summary

Cardiac resynchronization therapy (CRT) is a treatment for heart failure in patients who also suffer from ventricular dyssynchrony, a form of uncoordinated contraction of the ventricle (lower pumping chamber of the heart). In the past decade, CRT has become an established treatment for heart failure patients who are in normal rhythm, called sinus rhythm. An important subset of heart failure patients are those with atrial fibrillation (AF), who make up around 1 in 4 HF patients, and are over-represented amongst HF patients with more advanced symptoms. In heart failure patients with AF, CRT has proven not to be as effective as in sinus rhythm, due to competition between beats generated by the CRT device and beats conducted from the heart's own electrical conduction system. In the current study, we aim to test the hypothesis that ablating the AV node, which controls electrical conduction from the heart's atria (top chamber) to its ventricles (lower chambers), will improve survival and heart failure symptoms in CRT patients with co-existent AF. The results are important, because they will provide a way of passing on the benefits of CRT, such as improved survival, less heart failure symptoms, and better quality of life, to heart failure patients who also suffer from AF.

Conditions

Interventions

PROCEDURE

AV nodal ablation

Percutaneous catheter ablation of the AV node.

DRUG

Medical Ventricular Rate Control

Ventricular Rate Control with target ventricular rate of 90 beats per minute.

Sponsors & Collaborators

  • Medtronic

    collaborator INDUSTRY

  • Abbott Medical Devices

    collaborator INDUSTRY

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • University of Adelaide

    lead OTHER

Principal Investigators

  • Prashanthan Sanders, MBBS PhD · University of Adelaide

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2020-08-31
Completion
2020-08-31

Countries

  • Australia
  • Germany
  • Malaysia
  • New Zealand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01522898 on ClinicalTrials.gov